Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
NCT01963195
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
Icotinib
Sponsor
Anhui Medical University